[ad_1]
Frequent use of INNA-051 nasal spray can provide 96% protection against coronavirus. The claim stems from a study by the Australian pharmaceutical company responsible for creating the drug, Ena Respiratory, which was guided by Professor Miles Carroll, deputy director of Public Health England, and published Monday on the biomedical prepublications website medRxiv. .
According to The Telegraph, this new drug, which was created to increase human immunity to colds and flu, will move to the human testing phase following encouraging results obtained in animal tests. According to this study, INNA-051 prevents the virus from multiplying in the respiratory tract.
“We were surprised by the efficacy of the treatment,” said Dr. Christophe Demaison, managing director of Ena Respiratory. After tests were completed to ensure the initial purpose of the drug, the entire process was repeated to study the impact of the drug on Covid-19.
The results show that, by increasing the immune response, the spray drastically decreased the chance of infection, even when ferrets (animals used in the test phase) were deliberately infected with the virus.
The company is now seeking additional funding to accelerate the nasal spray’s clinical development and global distribution. INNA-051 is also the name of a small synthetic molecule that can be self-administered once or twice a week.
